Treatment of minimal residual disease in AML patients
The value of the ICML and highlights from the 2017 Annual Congress
Results of KEYNOTE-023 and pembrolizumab plus pomalidomide trials for multiple myeloma
Jesús San Miguel
Which is the best combination therapy in relapsed and refractory multiple myeloma?
Celebrating 60 years of successful allogenic transplant at EHA 2017